GRI BIO
GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.
GRI BIO
Industry:
Biopharma Biotechnology Life Science Pharmaceutical
Founded:
2009-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.gribio.com
Total Employee:
1+
Status:
Active
Contact:
(619) 400-1171
Total Funding:
4.38 M USD
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Inversago Pharma
Inversago Pharma is a specialized, preclinical-stage biotech company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Vybion
Vybion, Inc. is a development stage company.
Current Employees Featured
Founder
Official Site Inspections
http://www.gribio.com
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GRI Bio"
About Us - GRIbio
GRI Bio, Inc. 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037See details»
GRIbio | A New Approach to Inflammatory Diseases
We are advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. more +See details»
Corporate Governance - GRIbio
GRI Bio, Inc. 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037See details»
GRI Bio - Crunchbase Company Profile & Funding
GRI Bio is a biotechnology company that develops therapies to treat inflammatory diseases. Its cell-based therapies are developed to treat liver disease and …See details»
GRI Bio Company Profile | Management and Employees List
GRI Bio Profile and History. GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI™s Natural Killer T (NKT) cell-based …See details»
GRI Bio, Inc. | LinkedIn
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are …See details»
GRI Bio - Overview, News & Similar companies | ZoomInfo.com
Feb 2, 2024 GRI Bio Announces Pricing of $5.5 Million Public Offering LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a …See details»
GRI Bio Operations, Inc. - Drug pipelines, Patents, Clinical
Primary objectives: To evaluate the change in serum alanine transaminase [ALT] levels from Day 0 to Day 28, following daily doses of 4.5 or 6mg of GRI-0621 compared to placebo, in patients …See details»
GRI Bio Company Profile 2024: Stock Performance & Earnings
GRI Bio General Information Description. GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases …See details»
Study | GRIbio
US Sites: FLA Pulmonary, Allergy, and Sleep Medicine 4500 San Pablo Rd. S Jacksonville, FL 32224 Principal Investigator: Dr. Augustine Lee Primary Contact:See details»
GRI Bio, Inc. (GRI) Company Profile & Overview - Stock ... - Stock …
4 days ago GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, …See details»
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and …
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI …See details»
Board of Directors | GRIbio
GRI Bio, Inc. 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037See details»
生物技术公司GRI Bio宣布重塑企业品牌并推出新网站
2023年6月13日，生物技术公司GRI Bio, Inc.宣布重塑企业品牌并推出新网站gribio.com。公司目前正在推进其主要开发项目GRI-0621，作为每日一次的口服胶囊，用于治疗特发性肺纤维 …See details»
GRI Bio Operations, Inc. (GRI Bio Operations, Inc.) - 药物管线_专 …
了解GRI Bio Operations, Inc. (GRI Bio Operations, Inc.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 68篇新闻，疾病领域:免疫系统疾病，技术平台:小分子化药，药物:他 …See details»
GRI Stock Price & Charts | GRI Bio
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune …See details»
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare …
May 14, 2024 A live webcast of the event will be available on the Events page of the Investors section of the Company’s website (www.gribio.com). ... according to the World Health …See details»
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and …
LA JOLLA, CA, June 13, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell …See details»
GRO Biosciences – Delivering on the Promise of Protein Therapeutics
Oct 8, 2024 GRObio’s groundbreaking science redefines protein therapeutics with an expanded amino acid alphabetSee details»
Contact Us - GRIbio
Investor Relations Jenene Thomas JTC Team Phone: 908-824-0775 Email: [email protected]See details»